| Sumario: | This article focuses on evaluating the clinical and functional effects of alpha-1 antitrypsin replacement therapy in subjects with severe alpha-1 antitrypsin deficiency, a genetic disorder linked to pulmonary emphysema and chronic obstructive pulmonary disease (COPD). In a retrospective study of seven patients with both common and rare severe genotypes, at least 12 months of weekly intravenous augmentation therapy significantly improved quality of life, dyspnea (breathlessness), and six-minute walk test (6MWT) distance, while reducing the frequency of bronchial exacerbations. However, no significant changes were observed in standard lung function parameters or arterial blood gases. The study highlights potential benefits of replacement therapy on physical fitness and symptom relief but notes limitations including a small sample size and lack of a control group, suggesting the need for further research.
|
|---|